Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27584284 | 1.00 | KCNT1 (0.46) | KCNT1MEN1KMT2ANPC1LMNA | |
| SCHEMBL6718770 | 0.83 | AIMP2 (0.49) | MEN1KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL1928809 | 0.83 | MEN1 (0.43) | KCNT1MEN1KMT2AGPR84SSTR1 | |
| SCHEMBL27564431 | 0.83 | MEN1 (0.43) | KCNT1MEN1KMT2AGPR84SSTR1 | |
| SCHEMBL27564473 | 0.82 | KCNT1 (0.48) | KCNT1MEN1KMT2AGPR84SSTR1 | |
| SCHEMBL1928410 | 0.82 | KCNT1 (0.48) | KCNT1MEN1KMT2AGPR84SSTR1 | |
| SCHEMBL1927672 | 0.82 | KCNT1 (0.48) | KCNT1MEN1KMT2AGPR84SSTR1 | |
| SCHEMBL1928073 | 0.81 | CTSL (0.52) | MEN1KMT2ANPC1RAB9AECE1 | |
| SCHEMBL27564442 | 0.81 | CTSL (0.52) | MEN1KMT2ANPC1RAB9AECE1 | |
| SCHEMBL27469772 | 0.80 | SSTR1 (0.54) | MEN1KMT2ANPC1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | claimed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | claimed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | claimed |
| CN-1391474-A | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | claimed |
| EP-1589007-B1 | 5-membered heterocycle derivatives, production thereof and their use as medicaments | IPSEN PHARMA (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| EP-1228760-B1 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | IPSEN PHARMA (FR) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | disclosed |
| US-7291641-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2007-08-02 | — | — | US | disclosed |
| US-20070021390-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SCRAS | 2007-01-25 | — | — | US | disclosed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | disclosed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
| EP-1228760-A2 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021390-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, COMT | KCNT1 4620/4885MEN1 2860/4885KMT2A 4007/4885 |
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, SDHA | KCNT1 4583/4885MEN1 3085/4885KMT2A 3430/4885 |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | KCNT1 1067/4885MEN1 4429/4885KMT2A 3902/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | KCNT1 228/4885MEN1 4271/4885KMT2A 2676/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | KCNT1 764/4885MEN1 4280/4885KMT2A 3849/4885 |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, P2RX7 | KCNT1 582/4885MEN1 4015/4885KMT2A 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.